Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 192-198

  Cedres S ^a,b   Montero, M A ^a   Martinez, P ^a,b   Martinez, A ^a   Rodriguez Freixinos V ^a   Torrejon, D ^a   Gabaldon, A ^a   Salcedo, M ^a   Ramon y Cajal, S ^a   Felip, E ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

FOXO3; Malignant pleural mesothelioma; PI3K; Prognostic factor; PS6

Indexed keywords

ANTINEOPLASTIC AGENT; INITIATION FACTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6; TRANSCRIPTION FACTOR FKHRL1;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LUNG BIOPSY; MALE; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PLEURAL NEOPLASMS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 84861746074     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.02.022     Document Type: Article

References (50)

1. Martini N., McCormack P.M., Bains M.S., Kaser L.R., Burt M.E. Pleural mesothelioma. Ann Thorac Surg 1987, 43:113-120.
2. Carbone M., Kratzke R.A., Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 2002, 29(1):2-17.
3. Dogan A., Baris I., Dogan M., Emri S., Steele I. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006, 66(10):5063-5068.
4. De Luca A., Baldi A., Esposito V., Howard C.M., Bagella L. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 1997, 3(8):913-916.
5. Tward J.D., Wendland M.M., Shrieve D.C., Szabo A., Gaffney D.K. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006, 107(1):108-115.
6. Gulmez I., Kart L., Buyukoglan H., Er O., Balkanli S., Ozesmi M. Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J 2004, 11(4):287-290.
7. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
8. Van Meerbeeck, Gaafar R., Manegold C., VanKlaveren R., VanMarck E. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23:6881-6889.
9. Curran D., Sahmoud T., Therasse P., Van Meerbeeck J., Postmus P., Giuseppe G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998, 16:145-152.
10. *. Chest 1998, 113:723-731.
11. Flores R.M., Zakowski M., venkatraman E., Krug L., Rosenzweig K. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007, 2(10):957-965.
12. Jagadeeswaran R., Ma P.C., Seiwert T.Y., Jagadeeswaran S., Zumba O., Nallasura V., et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006, 66:352-361.
13. Destro A., Ceresoli G.L., Falleni M., Zucali P.A., Morenghi E., Bianchi P., et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006, 51:207-215.
14. Dazzi H., Hasleton P.S., Thatcher N., Wilkes S., Swindell R., Chatterjee A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGFR). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990, 61:924-926.
15. Thirkettle I., Harvey P., Hasleton P.S., Ball R.Y., Warn R.M. Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology 2000, 36:522-528.
16. Hoang C., Zhang X., Scott P., Guillaume T., Maddaus M. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 2004, 64:7479-7485.
17. Pass H.I., Robinson B.W., Testa J.R., Carbone M. Emerging translational therapies for mesothelioma. Chest 1999, 116:455S-460S.
18. Garland L., Rankin C., Gandara D., Rivkin S., Scott K. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2005, 25:2406-2413.
19. Mukohara T., Civiello G., Davis I.J., Taffaro M.L., Christensen J. Inhibition of the met receptor in mesothelioma. Clin Cancer Res 2005, 11:8122-8130.
20. Govindan R., Kratzke R., Herndon J., Niehans G., Vollmer R. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300-2304.
21. Patel M.r., Jacobson B.A., De A., Frizelle S.P., Janne P. Ras pathway activation in malignant mesothelioma. J Thorac Oncol 2007, 2(9):789-795.
22. Altomare D.A., Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464.
23. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
24. Engelman J., Luo J., Cantley L. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
25. Thompson J.E., Thompson C.B. Putting the rap on Akt. J Clin Oncol 2004, 22:4217-4226.
26. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
27. Ruggero D., Montanaro L., Ma L., Xu W., Londei P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004, 10:484-486.
28. Sonenberg N., Gingras A.C. The mRNA5' cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998, 10:268-275.
29. Opitz I., Soltermann A., Abaecherli M., Hinterberger M., Probst-Hensch N. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008, 33:502-506.
30. Kao S., Pavlakis N., Harvie R., Vardy J., Boyer M. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010, 16:5805-5813.
31. Halazun K.J., Aldoori A., Malik H.Z., Al-Mukhtar A., Prasad K.R. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008, 34(1):55-60.
32. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
33. Suzuki Y., Murakami H., Kawaguchi K., Taniguchi T., Fujii M. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2009, 2:181-188.
34. Varghese S., Chen Z., Bartlett D., Pingpank J., Libutti S. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer 2011, 117(2):361-371.
35. Volarevic S., Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Prog Nucleic Acid Res Mol Biol 2001, 65:101-127.
36. Klos K., Wyszomierski S., Sun M., Tan M., Zhou X. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006, 66(4):2028-2037.
37. Pantuck A.J., Seligson D.B., Klatte T., Yu H., Leppert J.Y. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Implications for molecular patient selection for targeted therapy. Cancer 2007, 109:2257-2267.
38. Pelloski C., Lin E., Zhang L., Yung A., Colman H., Liu H., et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Cancer Res 2006, 12(13):3935-3941.
39. McDonald M., Pelloski C., Ledoux A., Sun M., Raso G. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res 2008, 14(23):7832-7837.
40. Barbone D., Yang T., Morgan J., Gaudino G., Broaddus V. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 2008, 283(19):13021-13030.
41. Cristaudo A., Foddis R., Vivaldi A., Guglielmi G., Dipalma N. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007, 13:5076-5081.
42. Lopez-Rios F., Chuai S., Flores R., Shimizu S., Ohno T., Wakahara K. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006, 66:2970-2979.
43. Singhal S., Wiewrodt R., Malden L., Amin K., Matzie K. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003, 9:3080-3097.
44. Gordon G., Rockwell G., Godfrey P., Jensen R., Glickman J. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005, 11(12):4406-4414.
45. * is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010, 70(5):1916-1924.
46. Edwards J.G., Cox G., Andi A., Jones J.L., Walker R.A. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001, 85:863-868.
47. Strizzi L., Catalano A., Vianale G., Orecchia S., Casalini A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001, 193:468-475.
48. Hartman M., Esposito J.M., Yeap B.Y. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J Thorac Cardiovasc Surg 2010, 139:1233-1240.
49. Hoda M.A., Mohamed A., Ghanim B., Filipits M., Hegedus B., et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo synergism with chemotherapy. J Thorac Oncol 2011, 6(5):852-863.
50. Raymond E., Alexandre J., Faivre S., Vera K., Materman E. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004, 22:2336-2347.